WAT

Waters Corporation (WAT) - Q2 2007 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended June 30, 2007, and the six-month period ended on that date. Waters Corporation is a manufacturer of analytical instrument systems, including high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC), and mass spectrometry (MS) systems, as well as thermal analysis instruments. The company operates through two primary divisions: the Waters Division and the TA Division.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 17% in Q2 2007 and 15% YTD compared to the prior year. Growth was driven by new product introductions (ACQUITY UPLC, Q-Tof Premier, Synapt HDMS), increased pharmaceutical customer spending, and contributions from 2006 acquisitions (ERA, VICAM, Thermometric).
• Margin Compression: Gross margin decreased to 56.8% from 58.3% in the prior year periods. Management attributes this to a higher mix of instrument sales, higher manufacturing costs for new products, and unfavorable foreign currency impacts on UK-manufactured MS products.
• Operating Expenses: Selling and administrative expenses rose 15% QoQ, primarily due to merit increases, headcount additions, and acquisition-related costs. R&D expenses decreased slightly (3% QoQ) due to the absence of specific project expenses incurred in the prior year for late-2006 product launches.
• Restructuring: The prior year period included $3.0 million in restructuring charges (Q2) and $7.3 million (YTD) related to a 2006 cost reduction plan. No such charges were recorded in the current period.
• Debt Refinancing: In January 2007, the company entered a new credit agreement, borrowing $875 million to replace prior facilities. Total debt outstanding was $889.4 million as of June 30, 2007.

Outlook, Risks, and Management Commentary

• Guidance & Outlook: Management expects gross profit percentages to improve later in the year as volume efficiencies are achieved on new products. Selling and administrative expenses are anticipated to increase at a lower rate for the remainder of 2007.
• Share Repurchases: The company repurchased $156.5 million of stock YTD 2007. A new $500 million repurchase program authorized in February 2007 has $378 million remaining. The October 2005 program was completed.
• Legal Proceedings: Ongoing patent litigation with Agilent/HP regarding the "Alliance" pump continues in Germany and France. A settlement was reached in the UK in 2006. Management believes the outcome of remaining suits will not materially impact financial position.
• Risk Factors: Key risks include reliance on pharmaceutical industry capital spending (53% of sales), foreign currency fluctuations (68% of sales outside the U.S.), and supply chain disruptions from outside manufacturers.
• Accounting Changes: The company adopted FIN 48 (Accounting for Uncertainty in Income Taxes) in January 2007, resulting in a $3.9 million charge to retained earnings and $64.9 million in unrecognized tax benefits classified as long-term liabilities.

Investor Verification Checklist

• New Product Mix Impact: Verify if the anticipated improvement in gross margins materializes in Q3 as volume efficiencies are realized on new UPLC and MS systems.
• Pharma Spending Trends: Monitor capital expenditure trends in the pharmaceutical and biotechnology sectors, which account for over half of the company's revenue.
• Foreign Currency Exposure: Assess the impact of the strengthening U.S. dollar on future earnings, given that approximately 68% of sales are denominated in foreign currencies.
• Debt Covenants: Confirm continued compliance with the new 2007 Credit Agreement covenants (interest coverage ratio of 3.50:1 and leverage ratio of 3.25:1).
• Legal Resolution: Track the status of the German and French patent litigation to ensure no unexpected liability accruals are required.